Clicky

Xenon Pharmaceuticals Inc.(XENE)

Description: Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.


Keywords: Biopharmaceutical Pain Organic Compounds Chemical Compounds Gene Therapy Cardiovascular Disease Pharmaceutical Industries Osteoarthritis Analgesics Acne Neuropathic Pain Knee Lipoprotein Treatment Of Osteoarthritis Teva Pharmaceutical Industries Lipase Furans Indoles Lipoprotein Lipase Deficiency Treatment Of Cardiovascular Disease Alipogene Tiparvovec Glybera Postherpetic Neuralgia

Home Page: www.xenon-pharma.com

XENE Technical Analysis

3650 Gilmore Way
Burnaby, BC V5G 4W8
Canada
Phone: 604 484 3300


Officers

Name Title
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA Pres, CEO & Director
Ms. Sherry Aulin Chief Financial Officer
Dr. Christopher John Kenney M.D. Chief Medical Officer
Ms. Jodi Regts M.B.A., B.A., MBA VP of Corp. Affairs & Investor Relations
Ms. Andrea DiFabio J.D. Chief Legal Officer & Corp. Sec.
Ms. Shelley McCloskey B.A. Exec. VP of HR
Dr. Robin P. Sherrington Ph.D. Exec. VP of Strategy & Innovation
Dr. James R. Empfield Ph.D. Exec. VP of Drug Discovery
Ms. Sheila M. Grant M.B.A., M.Sc., MBA Exec. VP of R&D Operations
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.2172
Price-to-Sales TTM: 181.4446
IPO Date: 2014-11-05
Fiscal Year End: December
Full Time Employees: 149
Back to stocks